JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Long non-coding RNA HOXD-AS1 in cancer.

Cancer is one of the leading causes of death worldwide with a high risk of incidence and mortality. Long non-coding RNAs (lncRNAs) have been shown to participate in various biological processes, including tumorigenesis and progression. The HOXD-AS1 (also known as HAGLR and Mdgt) gene is located between the HOXD1 and HOXD3 genes in the HOXD cluster and has been reported to play a critical role in the development and progression of cancers. This review summarizes the current knowledge on the biological functions and mechanisms of HOXD-AS1 in different human cancers, including bladder, cervical, colorectal, gastric, ovarian, and prostate cancers, glioma, hepatocellular carcinoma, melanoma, osteosarcoma, and non-small cell lung cancer. The aberrant expression of HOXD-AS1 in these cancers was related with clinical features of patients with cancers. HOXD-AS1 regulates the growth, invasion, and migration of tumor cells through different underlying mechanisms. In conclusion, HOXD-AS1 may be considered as a promising diagnostic/prognostic biomarker or a novel therapeutic target for cancers.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app